COST-EFFECTIVENESS OF NEOADJUVANT PEMBROLIZUMAB PLUS CHEMOTHERAPY FOLLOWED BY ADJUVANT PEMBROLIZUMAB FOR HIGH-RISK EARLYSTAGE TRIPLE NEGATIVE BREAST CANCER IN COSTA RICA

被引：0
|
作者：
Rendon, A. M. [1 ]
Cordoba, R. [2 ]
Wurcel, V [3 ]
Rubino, R. [4 ]
Junqueira, M. [5 ]
Haiderali, A. [6 ]
Huang, M. [7 ]
Khandelwal, A. [8 ]
Gotarkar, S. [8 ]
机构：
[1] MSD Cent Amer, Panama City, Panama
[2] MSD, Panama City, Panama
[3] MSD Argentina, Buenos Aires, Argentina
[4] MSD Panama, Panama City, Panama
[5] MSD Brazil, Sao Paulo, Brazil
[6] Merck, N Wales, PA USA
[7] Merck & Co Inc, Rahway, NJ USA
[8] CHEORS, N Wales, PA USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE524
引用
收藏
页码：S152 / S152
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF NEOADJUVANT PEMBROLIZUMAB PLUS CHEMOTHERAPY FOLLOWED BY ADJUVANT PEMBROLIZUMAB FOR HIGH-RISK EARLYSTAGE TRIPLE-NEGATIVE BREAST CANCER (ETNBC) IN FRANCE
    Cagnan, L.
    Haiderali, A.
    Bensimon, L.
    Tehard, B.
    Carita, M.
    Khandelwal, A.
    Gandhi, J.
    Huang, M.
    [J]. VALUE IN HEALTH, 2023, 26 (12) : S61 - S61
  • [2] Cost-effectiveness of neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab for high-risk early-stage triple-negative breast cancer in Colombia
    Bruges Maya, R.
    Urrego, J. C.
    Marrugo, C.
    Wurcel, V.
    Khandelwal, A.
    Singh, J.
    Huang, M.
    Haiderali, A.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S286 - S286
  • [3] Cost-Effectiveness of Neoadjuvant Pembrolizumab plus Chemotherapy Followed by Adjuvant Pembrolizumab in Patients with High-Risk, Early-Stage, Triple-Negative Breast Cancer in Switzerland
    Andrea Favre-Bulle
    Min Huang
    Amin Haiderali
    Arjun Bhadhuri
    [J]. PharmacoEconomics - Open, 2024, 8 : 91 - 101
  • [4] Cost-Effectiveness of Neoadjuvant Pembrolizumab plus Chemotherapy Followed by Adjuvant Pembrolizumab in Patients with High-Risk, Early-Stage, Triple-Negative Breast Cancer in Switzerland
    Favre-Bulle, Andrea
    Huang, Min
    Haiderali, Amin
    Bhadhuri, Arjun
    [J]. PHARMACOECONOMICS-OPEN, 2024, 8 (01) : 91 - 101
  • [5] Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single-Agent Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer in the United States
    Min Huang
    Peter A. Fasching
    Amin Haiderali
    Weiguang Xue
    Chelsey Yang
    Wilbur Pan
    Zheng-Yi Zhou
    Peter Hu
    Mitashri Chaudhuri
    Celine Le Bailly De Tilleghem
    Nicolas Cappoen
    Joyce O’Shaughnessy
    [J]. Advances in Therapy, 2023, 40 : 1153 - 1170
  • [6] Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single-Agent Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer in the United States
    Huang, Min
    A. Fasching, Peter
    Haiderali, Amin
    Xue, Weiguang
    Yang, Chelsey
    Pan, Wilbur
    Zhou, Zheng-Yi
    Hu, Peter
    Chaudhuri, Mitashri
    De Tilleghem, Celine Le Bailly
    Cappoen, Nicolas
    O'Shaughnessy, Joyce
    [J]. ADVANCES IN THERAPY, 2023, 40 (03) : 1153 - 1170
  • [7] Letter to the Editor Regarding "Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single Agent Pembrolizumab for High-Risk Early-Stage Triple Negative Breast Cancer in the United States"
    Sorscher, Steven
    [J]. ADVANCES IN THERAPY, 2023, 40 (09) : 4111 - 4113
  • [8] Letter to the Editor Regarding “Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single Agent Pembrolizumab for High-Risk Early-Stage Triple Negative Breast Cancer in the United States”
    Steven Sorscher
    [J]. Advances in Therapy, 2023, 40 : 4111 - 4113
  • [9] Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab for treatment of high-risk, early-stage triple-negative breast cancer: A network meta-analysis
    Cortes, J.
    Haiderali, A.
    Huang, M.
    Pan, W.
    Fox, G. E.
    Park, J.
    Frederickson, A. M.
    Fasching, P. A.
    O'Shaughnessy, J.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S615 - S616
  • [10] COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB PLUS CHEMOTHERAPY AS NEOADJUVANT THERAPY AND CONTINUED AS A SINGLE AGENT AS ADJUVANT THERAPY FOR HIGH-RISK EARLY-STAGE TRIPLE-NEGATIVE BREAST CANCER IN GREECE
    Yfantopoulos, N.
    Athanasopoulos, C.
    Haiderali, A.
    Huang, M.
    Gountas, I
    Skroumpelos, A.
    Karokis, A.
    [J]. VALUE IN HEALTH, 2023, 26 (12) : S91 - S91
12345